



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:
Jack Stapleton *et al.*

Serial No.: 09/954,975

Filed: September 18, 2001

For: METHODS FOR TREATING HUMAN
IMMUNODEFICIENCY VIRUS
INFECTIONS WITH GALLIUM
COMPOSITIONS

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:033US/SLH

RECEIVED

MAR 15 2002

TECH CENTER 1600/2900	
RECEIVED OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 5, 2002	
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10108514/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 5, 2002



1646
+3

TELEPHONE: 512/445-5201
FACSIMILE: 512/536-3184

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

RECEIVED

March 5, 2002

MAR 15 2002

FILE: IOWA:033US

TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:

March 5, 2002

Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/954,975 "METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS WITH GALLIUM COMPOSITIONS" - Jack Stapleton et al.

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A12, C1-C2).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10108514/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb

Encl: as noted